Publications by authors named "Anna Maria Cafro"

Claim this Profile
T
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?
Viola Chiavetta, Martina Soldarini, Anna Maria Cafro, Paola Bertazzoni, Giuliana Lando

Transpl Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.
Mario Boccadoro, Angelo Belotti, Felice Bombaci, Sara Bringhen, Gabriele Buda, Anna Maria Cafro

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Anna Maria Cafro

Lancet Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, Silvia Mangiacavalli, Giulia Benevolo, Anna Maria Cafro

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Marc S Raab, Yael C Cohen, Fredrik Schjesvold, Kimberly Aardalen, Adwait Oka, Anna Maria Cafro

Leukemia· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Anna Maria Cafro

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni, Silvia Mangiacavalli, Anna Maria Cafro

Hematol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of isatuximab-pomalidomide-dexamethasone elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, Roberta Della Pepa, Alessandro Gozzetti, Anna Maria Cafro

Haematologica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
Arianna Zappaterra, Ivan Civettini, Anna Maria Cafro, Laura Pezzetti, Silvia Pierini

Blood Transfus· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.
Gianluca Cavallaro, Laura Paris, Paola Stefanoni, Chiara Pavoni, Silvia Mangiacavalli, Anna Maria Cafro

Mediterr J Hematol Infect Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Anna Maria Cafro

Cancer Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloma's multiple morphologies.
Silvia Cantoni, Andrea Galitzia, Valentina Mancini, Anna Maria Cafro, Roberto Cairoli

EJHaem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Marc S Raab, Yael C Cohen, Fredrik Schjesvold, Kimberly Aardalen, Adwait Oka, Anna Maria Cafro

Leukemia· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Michele Cavo, Francesca Gay, Meral Beksac, Lucia Pantani, Maria Teresa Petrucci, Anna Maria Cafro

Lancet Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Vittorio Montefusco, Alessandro Corso, Monica Galli, Ilaria Ardoino, Sara Pezzatti, Anna Maria Cafro

Br J Haematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.
Francesca Bonello, Stefano Pulini, Stelvio Ballanti, Massimo Gentile, Stefano Spada, Anna Maria Cafro

Cancers (Basel)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Sara Bringhen, Roberto Mina, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada

Leukemia· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Anna Maria Cafro

Blood· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
Alessandro Corso, Monica Galli, Silvia Mangiacavalli, Fausto Rossini, Andrea Nozza, Anna Maria Cafro

Am J Hematol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Alessandra Larocca, Federica Cavallo, Sara Bringhen, Francesco Di Raimondo, Anna Falanga, Anna Maria Cafro

Blood· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Alessandro Corso, Luciana Barbarano, Silvia Mangiacavalli, Mauro Spriano, Emilio P Alessandrino, Anna Maria Cafro

Leuk Lymphoma· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
Alessandro Corso, Patrizia Zappasodi, Luciana Barbarano, Maria Teresa Petrucci, Antonio Palumbo, Anna Maria Cafro

Leuk Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Anna Maria Cafro, Anna Maria Nosari

Leuk Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
Anna Maria Cafro, Luciana Barbarano, Anna Maria Nosari, Giovanna D'Avanzo, Michele Nichelatti

Clin Lymphoma Myeloma· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Alessandra Tedeschi, Marco Montillo, Elena Strocchi, Anna Maria Cafro, Elisabetta Tresoldi

Cancer Chemother Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis